Apyx medical corporation reports second quarter 2023 financial results and reaffirms full year 2023 financial outlook

Clearwater, fla.--(business wire)--apyx medical corporation (nasdaq:apyx) (the “company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as renuvion®, today reported financial results for its second quarter ended june 30, 2023, and reaffirms financial expectations for the full year ending december 31, 2023. second quarter 2023 financial summary: total revenue of $13.6 million, up 32% year-over-year. advanced energy revenue of $11.7 million, up 4.
APYX Ratings Summary
APYX Quant Ranking